The Technical Analyst
Select Language :
TCR2 Therapeutics Inc [TCRR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

TCR2 Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

TCR2 Therapeutics Inc is listed at the  Exchange

0.00% $1.480

America/New_York / 31 mai 2023 @ 16:00


TCR2 Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 58.11 mill
EPS: -4.20
P/E: -0.352
Earnings Date: Aug 07, 2023
SharesOutstanding: 39.26 mill
Avg Daily Volume: 0.325 mill
RATING 2023-05-31
B-
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Strong Sell
DE: Neutral
P/E: Neutral
Price To Book: Sell
QUARTER GROWTHS
4/211/222/223/224/221/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.352 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.06x
Company: PE -0.352 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 1.375 - 1.585

( +/- 7.09%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-06-01 Tang Kevin C Sell 4 394 800 Common Stock
2023-06-01 Ubs Oncology Impact Fund L.p. Sell 3 370 982 Common Stock
2023-06-01 Mpm Sunstates Fund, L.p. Sell 4 158 964 Common Stock
2023-06-01 Mpm Bioventures 2014, L.p. Sell 4 158 964 Common Stock
2023-06-01 Gadicke Ansbert Sell 3 370 982 Common Stock
INSIDER POWER
-89.42
Last 99 transactions
Buy: 1 629 400 | Sell: 23 030 678

Forecast: 01:40 - $1.845

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.480 (0.00% )
Volume 3.75 mill
Avg. Vol. 0.325 mill
% of Avg. Vol 1 154.74 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for TCR2 Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for TCR2 Therapeutics Inc

RSI

Intraday RSI14 chart for TCR2 Therapeutics Inc

Last 10 Buy & Sell Signals For TCRR

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            TCR2 Therapeutics Inc

TCRR

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Last 10 Buy Signals

Date Signal @
WAVESUSDMar 28 - 05:14$3.95
TAOUSDMar 28 - 05:14560.60
AQTUSDMar 28 - 05:141.940
CFXUSDMar 28 - 05:14$0.487
KOG.OLMar 27 - 08:08NOK749.50
SCHA.OLMar 27 - 08:05NOK346.80
BAKKA.OLMar 27 - 08:06NOK697.00
MLKUSDMar 28 - 05:090.409
KP3RUSDMar 28 - 05:0998.45
GTUSDMar 28 - 05:09$10.73

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.